Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SDZ HTF 919

Known as: HTF 919, SDZ HTF-919 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
REASONS FOR PERFORMING STUDY It has been shown that the selective 5-HT4 receptor agonist tegaserod induces an increase in… Expand
2001
2001
Tegaserod (HTF 919) is a selective 5‐HT4 receptor partial agonist in development for the treatment of irritable bowel syndrome. 
Highly Cited
2000
Highly Cited
2000
Tegaserod (HTF 919), a 5‐HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in… Expand
Highly Cited
1999
Highly Cited
1999
Previous studies have shown that the intestinal peristaltic reflex initiated by mucosal stimulation is mediated by release of 5… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1999
Highly Cited
1999
Tegaserod (HTF 919) is a new drug being developed for gastrointestinal motility disorders. Because other gastrointestinal… Expand
1999
1999
This study assessed the pharmacokinetic profiles of administering tegaserod (HTF 919) at different time intervals with respect to… Expand
Highly Cited
1998
Highly Cited
1998
BACKGROUND & AIMS The peristaltic reflex induced by mucosal stimuli is mediated by intrinsic sensory calcitonin gene-related… Expand
Highly Cited
1997
Highly Cited
1997
Effects of the nonbenzamide 5-hydroxytryptamine4 agonist SDZ HTF 919 on gastrointestinal motility are unclear. Our aim was to… Expand
1997
1997
To explore the pharmacodynamic effects of the new promotile agent SDZ HTF 919, a selective partial 5‐HT4 receptor agonist, in… Expand